{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:24:11Z","timestamp":1769001851368,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clml.2021.07.030","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:52:46Z","timestamp":1627905166000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient"],"prefix":"10.1016","volume":"22","author":[{"given":"Vadlamani Surya","family":"Prakash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanshu","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur Nandan","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2021.07.030_bib0001","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.030_bib0002","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2021.07.030_bib0003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","article-title":"Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.clml.2021.07.030_bib0004","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2021.07.030_bib0005","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","volume":"18","author":"Nademanee","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2021.07.030_bib0006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","article-title":"Plerixafor Plus Granulocyte Colony-stimulating factor for patients with Non-Hodgkin Lymphoma and multiple myeloma: long-term follow-up report","volume":"24","author":"Micallef","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2021.07.030_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10428194.2017.1324161","article-title":"Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma","volume":"59","author":"Milone","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2021.07.030_bib0008","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.clml.2021.07.030_bib0009","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- Plerixafor versus Granulocyte Colony-Stimulating Factor +\/- Plerixafor in the Lenalidomide Era","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.clml.2021.07.030_bib0010","first-page":"1141","article-title":"Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2019","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.clml.2021.07.030_bib0011","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2020.08.021","article-title":"AIIMS Myeloma Group. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2021.07.030_bib0012","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2021.07.030_bib0013","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41409-018-0152-2","article-title":"Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma","volume":"53","author":"Chua","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2021.07.030_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2019.10.008","article-title":"Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization","volume":"22","author":"Bakeer","year":"2020","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.clml.2021.07.030_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21563","article-title":"UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy","volume":"33","author":"Douglas","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.clml.2021.07.030_bib0016","article-title":"Is absence of CD56 a predictive factor for peripheral blood stem cell mobilization failure in patients with multiple myeloma?","author":"G\u00f6\u00e7er","year":"2020","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.clml.2021.07.030_bib0017","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.07.030_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106215","article-title":"Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization","volume":"85","author":"Andritsos","year":"2019","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:09Z","timestamp":1761871089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502100313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S215226502100313X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.030","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}